Primary Outcome Measures:
- Compare the PTH-associated change from baseline at Month 3 of procollagen peptide P1NP, in subjects previously treated with Risedronate or Alendronate [ Time Frame: at Month 3 ] [ Designated as safety issue: No ]
Secondary Outcome Measures:
- Compare changes from baseline for subjects previously treated with Risedronate or Alendronate for:
P1NP & other biomarkers including bone-specific alkaline phosphatase, osteocalcin, serum CTX, urine NTX [ Time Frame: at 0.5, 1, 2, 3, 4, 5, 6, & 12 months of treatment ] [ Designated as safety issue: No ]
- Compare changes from baseline for subjects previously treated with Risedronate or Alendronate for:
Lumbar spine & hip BMD measured by DXA [ Time Frame: after 6 & 12 months of treatment ] [ Designated as safety issue: No ]
- Compare changes from baseline for subjects previously treated with Risedronate or Alendronate for:
Bone quality parameters captured by central quantitative computed tomography (QCT) [ Time Frame: after 12 months of treatment ] [ Designated as safety issue: No ]
All subjects will be treated with teriparatide (human, recombinant PTH[1-34])(human, recombinant PTH[1-34]), 20 microgram subcutaneously daily for 12 months. Subjects will consist of 290 postmenopausal women previously treated with either risedronate or alendronate for at least 24 months. An approximately equal number of subjects will have been previously treated with risedronate and alendronate, and the subjects will be balanced with regard to duration of previous treatment.